Roche and Xenon ink pact on anemia therapies

Roche Holdings has agreed to a deal with Xenon to develop new anemia therapies. Roche will invest $7 million and pay up to $44 million in milestones for the first product. Roche gains an option to commercialize protein therapeutics targeting hemojuvelin as well as a licensing option for small molecule inhibitors of HJV.

- read the AFX report on the deal

Related Articles:
Roche, Halozyme enter licensing pact. Report
Xenon licenses out pain drug to Takeda. Report